Αποτελέσματα Αναζήτησης
8 Νοε 2023 · Zepbound is the first obesity treatment that activates both GIP and GLP-1 hormone receptors, and can help adults lose weight and keep it off. It was approved by the FDA in November 2023 based on clinical trial results showing substantial weight loss and safety data.
The US Food and Drug Administration approved the type 2 diabetes drug tirzepatide for use in chronic weight management Wednesday, making official the use of a medicine already widely prescribed...
8 Νοε 2023 · The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16...
8 Νοε 2023 · The F.D.A. approved Zepbound for people who have a body mass index — a much-criticized metric — of 30 or greater, which technically qualifies them as having obesity, or those with a B.M.I....
9 Νοε 2023 · On Nov. 8, the U.S. Food and Drug Administration (FDA) approved tirzepatide (which will be sold under the brand name Zepbound), to treat overweight and obesity. Made by Eli Lilly and Co., the...
8 Νοε 2023 · An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy.
